Eli Lilly and Company (LLY)
NYSE • Healthcare
October 2, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Eli Lilly and Company keeps $31 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 26 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Eli Lilly and Company beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 5, as revenue of about $23.0 billion topped the about $20.7 billion consensus by +11.1% and adjusted EPS of $8.38 beat the $6.28 estimate by +33.4%. Revenue rose 47.7% from a year ago, led by Cardiometabolic Health at about $18.4 billion, up 61.8%, while the U.S. remained the largest region at about $14.4 billion, up 33.3%, and Europe contributed about $4.1 billion, up 59.9%. Gross margin was near 86% and operating margin about 40%, and net income climbed 25.3% to about $7.1 billion from $5.66 billion a year earlier. Operating cash flow came in at about $10.7 billion, the company repurchased about $1.6 billion of stock and paid $1.55 billion in dividends, and next-period consensus EPS is $9.48 on revenue of $21.65 billion.
Next report — what to expect
Eli Lilly and Company reports on October 29, 2026. Wall Street is looking for EPS of $9.92 on revenue of $22.32 billion. For trailing context, revenue grew +47.7% year over year last quarter. Lilly has beaten EPS in 7 of 8 most recent quarters, so traders may focus on guidance updates alongside the headline figures.
About Eli Lilly and Company
Eli Lilly and Company researches, develops, and commercializes human medicines, operating as a large pharmaceutical company listed on the NYSE as LLY. Its portfolio spans diabetes, oncology, immunology, neuroscience, and other specialty therapies, and it recorded $65.2 billion of revenue in FY2025.
Today's Snapshot
LLY closed 0.6% lower at 1142.85, while its sector was flat. Eli Lilly gained approval from the U.S. drug regulator to use Jaypirca, its cancer drug, first for certain blood cancers.
Trading Volume
Below 10d avg (2.3M)
2M
vs S&P 500 Today
Underperforming Market
-1.39%
Updated: October 2, 2026 at 20:24 UTC
LLY Headlines
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1077.26 - $1162.75Sell
- RSI (14)43.01Neutral
- Stochastic %K (14, 3, 3)26.48Neutral
- MACD Level (12, 26)-3.04Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.